Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Blood Clot Clear all
Completed No phase listed Observational

Myeloproliferative Neoplasms (MPN) and COVID-19

NCT04385160
View directory record Official record
Conditions
Myeloproliferative Neoplasm, COVID
Interventions
Not listed
Lead sponsor
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Other
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Phase 4 Interventional

Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II)

NCT00289042
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Enoxaparin
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 30, 2007 · Synced Jul 23, 2026, 6:22 AM EDT
Terminated Phase 2 Interventional Results available

Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina

NCT00770770
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
3
States / cities
Lexington, Kentucky • Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Jul 23, 2026, 6:22 AM EDT
Suspended Not applicable Interventional

CLEANer Aspiration for Pulmonary Embolism

NCT06189313
View directory record Official record
Conditions
Pulmonary Embolism, Acute Pulmonary Embolism, Cardiovascular Diseases, Venous Thromboembolism
Interventions
Cleaner Pro Thrombectomy System
Device
Lead sponsor
Argon Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 23, 2026, 6:22 AM EDT
Not listed Phase 2 Interventional

Protect the Head to Head Study

NCT05684146
View directory record Official record
Conditions
Embolism
Interventions
Emboliner Embolic Protection, Sentinel Cerebral Protection
Device
Lead sponsor
Emboline
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
New York, New York • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Jul 23, 2026, 6:22 AM EDT
Recruiting Early Phase 1 Interventional

Supplemental Oxygen in Pulmonary Embolism (SO-PE)

NCT05891886
View directory record Official record
Conditions
Pulmonary Embolism, Venous Thromboembolism, Metabolomics, Oxygen Inhalation Therapy
Interventions
Oxygen Therapy, Non-rebreather mask
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2025 · Synced Jul 23, 2026, 6:22 AM EDT
Completed No phase listed Observational

The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings

NCT00830570
View directory record Official record
Conditions
Embolism and Thrombosis, Embolism, Vascular Diseases, Warfarin, Venous Thromboembolism, Thrombosis, Thromboembolism
Interventions
CYP 2C9 and VKORC1 Testing for Warfarin
Other
Lead sponsor
Medco Health Solutions, Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
1,635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Franklin Lakes, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 15, 2010 · Synced Jul 23, 2026, 6:22 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

National Eye Institute Biorepository for Retinal Diseases

NCT01496625
View directory record Official record
Conditions
Age-Related Macular Degeneration, Diabetic Retinopathy, Von Hippel-Lindau Syndrome, Retinal Disease, Retinal Vein Occlusion
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years to 120 Years
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Phase 3 Interventional Results available

Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation

NCT00781391
View directory record Official record
Conditions
Stroke, Atrial Fibrillation, Embolism
Interventions
warfarin tablets, Edoxaban tablets (high dose regimen-60mg), Edoxaban tablets (low dose regimen-30mg), placebo warfarin, placebo edoxaban
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
21 Years and older
Enrollment
21,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
316
States / cities
Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 308 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants

NCT03224260
View directory record Official record
Conditions
Thrombosis
Interventions
BMS-986177, Matched Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Jul 23, 2026, 6:22 AM EDT
Terminated Phase 4 Interventional Results available

PREvention of VENous ThromboEmbolism Following Radical Prostatectomy

NCT03006562
View directory record Official record
Conditions
Prostate Cancer, Venous Thromboembolism, Lymphocele After Surgical Procedure, Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Subcutaneous Heparin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Not applicable Interventional Results available

Randomized Trial of Interventions to Improve Warfarin Adherence

NCT00904982
View directory record Official record
Conditions
Atrial Fibrillation, Deep Vein Thrombosis, Dilated Cardiomyopathies
Interventions
Financial Incentive and Med-eMonitor, 2Med-eMonitor
Behavioral · Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Jul 23, 2026, 6:22 AM EDT
Terminated Phase 4 Interventional Results available

Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment

NCT04707625
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Aflibercept Ophthalmic
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Jul 23, 2026, 6:22 AM EDT
Recruiting No phase listed Observational

Clinical Performance Evaluation of Native Whole Blood Samples of Patients on DOACs With the Perosphere ClotChek™

NCT07012291
View directory record Official record
Conditions
Coagulation
Interventions
Whole Blood Clotting Time
Device
Lead sponsor
Perosphere Technologies Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Danbury, Connecticut • Rockville, Maryland • Denville, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 23, 2026, 6:22 AM EDT
Withdrawn Phase 4 Interventional

ATHERO: Advanced Technology Halting Early Re-Stenosis and Occlusion

NCT00407940
View directory record Official record
Conditions
Arterial Occlusive Disease, Intermittent Claudication
Interventions
Lower extremity Atherectomy and Cryoplasty
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Phase 2 Interventional

Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices

NCT00073515
View directory record Official record
Conditions
Catheters, Indwelling
Interventions
Alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Phase 1 Interventional

Dose Response to Topical Glyceryl Trinitrate in Patients With Raynaud's Phenomenon

NCT00700518
View directory record Official record
Conditions
Raynaud's Phenomenon
Interventions
placebo cream, Glyceryl Trinitrate
Drug
Lead sponsor
Procris Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 29, 2008 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Not applicable Interventional

D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months

NCT00720915
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Discontinue anticoagulant therapy (Negative d-dimer), Continue on anticoagulant therapy (positive d-dimer)
Other
Lead sponsor
McMaster University
Other
Eligibility
18 Years to 75 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Iowa City, Iowa • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Jul 23, 2026, 6:22 AM EDT
Completed No phase listed Observational

Heparin-Induced Thrombocytopenia Registry

NCT00456326
View directory record Official record
Conditions
Heparin-Induced Thrombocytopenia
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2008 · Synced Jul 23, 2026, 6:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prevalence of MTHFR Polymorphisms in Venous Disease

NCT01993914
View directory record Official record
Conditions
Varicose Veins, MTHFR, Venous Disease, Thrombosis
Interventions
Not listed
Lead sponsor
Health Diagnostic Laboratory, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2014 · Synced Jul 23, 2026, 6:22 AM EDT
Completed No phase listed Observational

Emulation of the RECORD3 Trial Using Healthcare Claims Data

NCT07599384
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolus
Interventions
Rivaroxaban, Enoxaparin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
149,248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 23, 2026, 6:22 AM EDT
Recruiting Phase 3 Interventional

DOAC - Dosing Options in AntiCoagulation Prophylaxis

NCT07005024
View directory record Official record
Conditions
Cancer, VTE (Venous Thromboembolism)
Interventions
Apixaban 2.5 mg twice daily, Apixaban 5 mg once daily, No anticoagulation
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Evaluating the Safety and Preliminary Efficacy of sFilm-FS in Controlling Parenchymal Bleeding During Elective Hepatic Surgery

NCT04660721
View directory record Official record
Conditions
Hemostasis, General Surgery
Interventions
sFilm-FS, TACHOSIL®
Combination Product
Lead sponsor
Sealantium Medical Ltd.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Jul 23, 2026, 6:22 AM EDT
Completed No phase listed Observational

EXCEL Clinical Trial (Universal Registry)

NCT01205789
View directory record Official record
Conditions
Chronic Coronary Occlusion, Left Main Coronary Artery Disease, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
Not listed
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Jul 23, 2026, 6:22 AM EDT